| |
| |
|
| Insider
Information: |
Sanofi-Aventis |
| Relationship: |
10% Owner |
| City: |
Paris |
| State: |
I0 |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
11 |
|
| Direct
Shares |
75,668,031 |
|
|
Indirect Shares
|
26,048,661 |
|
|
| Direct
Value |
$2,826,957,638 |
|
|
|
Indirect Value
|
$1,890,589,078 |
|
|
| Total
Shares |
101,716,692 |
|
|
| Total
Value |
$4,717,546,717 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
5
|
|
Stock
price went up :
|
0
|
2
|
| Stock
price went down : |
1
|
3
|
| |
|
|
|
Gain/Loss Ratio : |
-1.0
|
-1.0
|
| Percentage
Gain/Loss : |
 -17.8%
|
-3.6%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Regulus Therapeutics Inc. |
RGLS |
10% Owner |
|
0 |
2014-02-04 |
5,053,779 |
Premium* |
|
|
Humanigen Inc |
HGEN |
Former 10% owner |
2013-01-31 |
0 |
2013-01-31 |
579,030 |
Premium* |
|
|
Glycomimetics Inc |
GLYC |
10% Owner |
|
0 |
2013-11-06 |
1,193,625 |
Premium* |
|
|
Regeneron Pharmaceuticals Inc |
REGN |
|
2020-05-29 |
0 |
2020-06-09 |
279,766 |
Premium* |
|
|
Alnylam Pharmaceuticals Inc |
ALNY |
10% Owner |
|
0 |
2017-05-31 |
10,554,134 |
Premium* |
|
|
Scynexis Inc |
SCYX |
10% Owner |
|
0 |
2014-05-07 |
1,677,057 |
Premium* |
|
|
Voyager Therapeutics, Inc. |
VYGR |
Former 10% owner |
2015-11-10 |
0 |
2015-11-16 |
2,477,941 |
Premium* |
|
|
Fulcrum Therapeutics, Inc. |
FULC |
10% Owner |
2019-07-22 |
0 |
2019-07-22 |
558,035 |
Premium* |
|
|
Inozyme Pharma, Inc. |
INZY |
10% Owner |
2020-07-28 |
0 |
2020-07-28 |
520,125 |
Premium* |
|
|
Icosavax, Inc. |
ICVX |
10% Owner |
2021-08-02 |
0 |
2021-08-02 |
3,155,169 |
Premium* |
|
|
Translate Bio, Inc. |
TBIO |
10% Owner |
2021-09-14 |
75,668,031 |
2021-09-14 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
85 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RGLS |
Regulus Therapeutics Inc. |
10% Owner |
– – • |
2012-10-04 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
3,749,999 |
|
- |
|
| GLYC |
Glycomimetics Inc |
10% Owner |
– – • |
2013-11-06 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,193,625 |
|
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
10% Owner |
– – • |
2014-02-27 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
8,766,338 |
|
- |
|
| SCYX |
Scynexis Inc |
10% Owner |
– – • |
2014-05-07 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,677,057 |
|
- |
|
| VYGR |
Voyager Therapeutics, Inc... |
Former 10% owner |
– – – |
2015-11-10 |
4 |
A |
$0.00 |
$0 |
I/I |
2,352,941 |
2,352,941 |
0 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
10% Owner |
– – • |
2019-07-22 |
4 |
A |
$0.00 |
$0 |
I/I |
464,285 |
464,285 |
0 |
- |
|
| INZY |
Inozyme Pharma, Inc. |
10% Owner |
– – • |
2020-07-28 |
4 |
A |
$0.00 |
$0 |
I/I |
438,875 |
438,875 |
0 |
- |
|
| ICVX |
Icosavax, Inc. |
10% Owner |
– – • |
2021-08-02 |
4 |
A |
$0.00 |
$0 |
I/I |
3,088,502 |
3,088,502 |
0 |
- |
|
| RGLS |
Regulus Therapeutics Inc. |
10% Owner |
– – • |
2014-02-04 |
4 |
B |
$7.67 |
$9,999,993 |
I/I |
1,303,780 |
5,053,779 |
1.5 |
- |
|
| HGEN |
Humanigen Inc |
Former 10% owner |
– – – |
2013-01-31 |
4 |
B |
$8.00 |
$700,000 |
I/I |
87,500 |
579,030 |
0.01 |
- |
|
| VYGR |
Voyager Therapeutics, Inc... |
Former 10% owner |
– – – |
2015-11-16 |
4 |
B |
$14.00 |
$1,750,000 |
I/I |
125,000 |
2,477,941 |
0.01 |
- |
|
| ICVX |
Icosavax, Inc. |
10% Owner |
– – • |
2021-08-02 |
4 |
B |
$15.00 |
$1,000,005 |
I/I |
66,667 |
3,155,169 |
1.5 |
- |
|
| FULC |
Fulcrum Therapeutics, Inc... |
10% Owner |
– – • |
2019-07-22 |
4 |
B |
$16.00 |
$1,500,000 |
I/I |
93,750 |
558,035 |
1.5 |
- |
|
| INZY |
Inozyme Pharma, Inc. |
10% Owner |
– – • |
2020-07-28 |
4 |
B |
$16.00 |
$1,300,000 |
I/I |
81,250 |
520,125 |
1.5 |
- |
|
| TBIO |
Translate Bio, Inc. |
10% Owner |
– – • |
2021-09-14 |
4 |
B |
$38.00 |
$2,147,483,647 |
D/D |
71,983,597 |
75,668,031 |
2.45 |
% |
|
| ALNY |
Alnylam Pharmaceuticals I... |
10% Owner |
– – • |
2014-03-25 |
4 |
B |
$66.88 |
$23,036,682 |
I/I |
344,448 |
9,110,786 |
1.5 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
10% Owner |
– – • |
2016-02-01 |
4 |
B |
$69.75 |
$14,300,843 |
I/I |
205,030 |
10,256,633 |
1.5 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
10% Owner |
– – • |
2017-05-31 |
4 |
B |
$71.87 |
$21,381,397 |
I/I |
297,501 |
10,554,134 |
1.5 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
10% Owner |
– – • |
2015-01-26 |
4 |
B |
$95.00 |
$61,507,560 |
I/I |
647,448 |
9,954,485 |
1.5 |
- |
|
| ALNY |
Alnylam Pharmaceuticals I... |
10% Owner |
– – • |
2015-01-29 |
4 |
B |
$95.00 |
$9,226,210 |
I/I |
97,118 |
10,051,603 |
1.5 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
10% Owner |
– – • |
2014-01-27 |
4 |
B |
$269.77 |
$20,386,044 |
I/I |
74,685 |
15,891,638 |
1.5 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
10% Owner |
– – • |
2014-06-27 |
4 |
AB |
$272.70 |
$13,769,092 |
I/I |
50,000 |
20,258,841 |
0 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
10% Owner |
– – • |
2014-01-28 |
4 |
B |
$273.44 |
$23,184,321 |
I/I |
83,235 |
15,974,873 |
1.5 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
10% Owner |
– – • |
2014-02-05 |
4 |
B |
$274.64 |
$58,367,107 |
I/I |
206,978 |
16,581,109 |
1.5 |
- |
|
| REGN |
Regeneron Pharmaceuticals... |
10% Owner |
– – • |
2014-06-30 |
4 |
AB |
$275.68 |
$60,010,479 |
I/I |
212,400 |
20,471,241 |
0 |
- |
|
85 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
